TNFRSF4 Antibodies

Structure of TNFRSF4

The protein encoded by the TNFRSF4 gene is a transmembrane receptor with a molecular weight of approximately 28-30 kDa. The molecular weight of this protein varies among different species, mainly due to glycosylation modifications and minor changes in the transmembrane region.

This protein is composed of approximately 240 amino acids and includes a signal peptide, an extracellular ligand-binding domain rich in cysteines, a single transmembrane region, and a cytoplasmic tail. Its extracellular domain is composed of three conserved cysteine-rich domains (CRDs), forming a typical tumor necrosis factor receptor superfamily fold. The intracellular region lacks inherent enzymatic activity and mainly activates downstream NF-κB and MAPK signaling pathways by recruiting TRAF adaptor proteins. The ligand-binding pocket is formed by the CRD2 and CRD3 domains, and the key arginine residues are responsible for the specific recognition and binding to the ligand OX40L.

Fig. 1 The TNFSF4 gene as represented in the NCBI database.¹

Key structural properties of TNFRSF4:

• Typical extracellular domains of the tumor necrosis factor receptor (TNFR) superfamily
• Fixed to the cell membrane by a single transmembrane region
• Intracellular area without catalytic function, but contains specific motif to raise a downstream signaling molecules
• Maintain structural stability through disulfide bonds and ensure specific binding with the ligand OX40L

Functions of TNFRSF4

The main function of the protein encoded by the TNFRSF4 gene is to regulate the activation and proliferation of T cells. However, it is also widely involved in various immune-related physiological and pathological processes, including the formation of immune memory and the regulation of autoimmunity.

Unlike most receptors that require the aggregation of multiple ligands to be efficiently activated, TNFRSF4 has a high affinity binding with OX40L, which can rapidly initiate a strong and sustained signaling cascade. This highlights its crucial "amplifier" role in initiating and maintaining adaptive immune responses.

Applications of TNFRSF4 and TNFRSF4 Antibody in Literature

1. Ria, Massimiliano, et al. "A common polymorphism in the promoter region of the TNFSF4 gene is associated with lower allele-specific expression and risk of myocardial infarction." PLoS One 6.3 (2011): e17652. https://doi.org/10.1371/journal.pone.0017652

Studies have shown that the rs45454293 polymorphism in the promoter region of the TNFSF4 gene is related to its expression level. Carrying the T allele can reduce transcriptional activity and decrease the expression of TNFSF4, thereby increasing the risk of myocardial infarction in women. This variation works by influencing the binding of transcription factors.

2. Murphy, Catherine, et al. "In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma." Plos one 19.5 (2024): e0303643. https://doi.org/10.1371/journal.pone.0303643

Studies have shown that in drug-resistant neuroblastoma models, low expression of TNFRSF4 is associated with enhanced metastasis ability of tumor cells and is an independent risk factor for poor prognosis in patients, which can affect event-free survival and overall survival.

3. Guo, Runqi, et al. "Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity." Frontiers in Immunology 16 (2025): 1637317. https://doi.org/10.3389/fimmu.2025.1637317

Research has found that microwave ablation can affect the tumor microenvironment by regulating the OX40L/TNFRSF4 axis: reducing the function of CTLA-4+ Tregs, enhancing the cytotoxicity of CD8+ T cells, and increasing the intracellular CD8+/Treg ratio, providing a new basis for combined immunotherapy.

4. Ma, Heng, et al. "Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma." BMC cancer 22.1 (2022): 543. https://doi.org/10.1186/s12885-022-09654-6

Studies have confirmed that TNFRSF4 can serve as a novel prognostic marker in endometrial cancer. Its expression level is positively correlated with CD4+, CD8+ T cells and Tregs infiltration within the tumor, and is significantly associated with the survival prognosis of patients.

5. Gu, Siyu, et al. "Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia." Cancer Cell International 20.1 (2020): 146. https://doi.org/10.1186/s12935-020-01213-y

Studies have confirmed that in non-M3 type acute myeloid leukemia, high expression of TNFRSF4 is significantly associated with TP53, FLT3, NPM1 gene mutations and poor prognosis, and the overall survival of patients is significantly shortened, suggesting that it can serve as a potential prognostic biomarker.

Creative Biolabs: TNFRSF4 Antibodies for Research

Creative Biolabs specializes in the production of high-quality TNFRSF4 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom TNFRSF4 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our TNFRSF4 antibodies, custom preparations, or technical support, contact us at email.